Pharmacia and Upjohn gains Pap screening device:
This article was originally published in Clinica
Executive Summary
Pharmacia & Upjohn has struck a joint marketing agreement with Trylon, a privately-owned medtech developer in Torrance, California. The deal relates to Trylon's Pap Plus Speculoscopy (PPS) which is to be launched in March. Trylon's technology is based on the use of chemical light technology in diagnostics and other applications. PPS is the company's first product and combines a visual examination speculoscopy with the standard Pap smear into simple primary cervical screening tests.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.